Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Soft Drinks Showdown: 2 Stocks To Buy, 2 To Avoid

By Josh Enomoto, InvestorPlace Contributor

Beverage companies have been one of the best stocks to buy this year, but tight competition makes selectivity all the more important.

3 International Banking Stocks to Leave in the Vault

By Josh Enomoto, InvestorPlace Contributor

Don't be fooled by sharply discounted international banking stocks -- there are still fundamental uncertainties yet to be worked out.

Novavax Banking on Clinical Trials to Boost NVAX Stock

By Josh Enomoto, InvestorPlace Contributor

Tight-roping Novavax could set up phenomenal gains for NVAX stock should its vaccination trials improve.

Black Friday: Amazon Stock Takes Larger Bite out of Shrinking Pie (AMZN)

By Josh Enomoto, InvestorPlace Contributor

Record online sales during Black Friday weekend is a likely boost for Amazon stock, but tepid retail growth overall is a huge problem.

Industry Stalwart 3M Looking to Finish Strong (MMM)

By Josh Enomoto, InvestorPlace Contributor

Renowned innovation firm 3M is on a comeback after MMM fell behind for much of the year, but can the bulls hold on?

Will This Be Enough to Revive Alcoa (AA) Stock?

By Josh Enomoto, InvestorPlace Contributor

Aggressive changes in Alcoa's business structure has spurred some buying activity for AA stock, but aluminum's bear market looms larger.

Can Strategy Shift Reverse CSX Stock’s 2015 Losses?

By Josh Enomoto, InvestorPlace Contributor

After a sharp downturn, CSX stock has recently rebounded strongly in the markets: can new efficiency measures keep CSX improving?

Clovis Oncology (CLVS) Knocked Out By FDA Inquiry

By Josh Enomoto, InvestorPlace Contributor

Clovis Oncology Inc suffered a massive setback to its lung cancer treatment program, erasing years of gains made by CLVS stock.

A Look at French Stocks in the Aftermath of Paris

By Josh Enomoto, InvestorPlace Contributor

In the wake of the barbaric Paris attack, are French stocks at increased risk for volatility in the markets?

Critical Earnings Showdown For Walmart, Target (WMT, TGT)

By Josh Enomoto, InvestorPlace Contributor

Cash-strapped consumers and market volatility are huge problems for big-box retailers Walmart (WMT) and Target (TGT) ahead of Q3 results.

Load More